Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexes containing a 1,2-bis(aminomethyl)cyclobutane stable ligand and lactic acid as the leaving group. Its antitumour activity results from the formation of DNA-drug adducts, mainly as GG and AG intra-strand cross-links. Lobaplatin influences the expression of the c-myc gene, which is involved in oncogenesis, apoptosis and cell proliferation[3]. Lobaplatin and paclitaxel inhibited SGC-7901 cell growth in a concentration and timedependent manner, with IC25 values at 48h of 1.97±0.17µg/ml and 1.98±0.19 ng/ml, respectively. Lobaplatin did not affect cyclin D1 and CDK4 protein expression, while cyclin E1 and CDK2 levels were significantly increased, with cyclin B1 amounts markedly decreased (p<0.05). More S phase cells were observed after lobaplatin treatment compared with controls (60.03±1.25 vs. 18.69±0.96%; p<0.05). Lobaplatin and paclitaxel combination did not affect cyclin D1 and CDK4 protein levels (p>0.05); meanwhile, cyclin E1 and CDK2 levels were increased, with reduced cyclin B1 amounts, compared with control values (p<0.05)[4].Lobaplatin inhibited proliferation of human HCC cells in a dose-dependent manner. For the most sensitive SMMC-7721 cells, lobaplatin arrested cell cycle progression in G1 and G2/M phases time-dependently which might be associated with the down-regulation of cyclin B, CDK1, CDC25C, phosphorylated CDK1 (pCDK1), pCDK4, Rb, E2F, and pRb, and the up-regulation of p53, p21, and p27[5].Lobaplatin inhibited the proliferation of human gastric cancer cells and induced apoptosis, which may be associated with the up-regulation of Bax expression, poly(ADP-ribose) polymerase (PARP) cleavage, p53 expression and the reduction of Bcl-2 expression[6].
China, Beijing
... 展开 >> Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Recruiting
Beijing, Beijing, China, 100021
Contact: Zefen Xiao, MD 收起 <<
IMRT With or Without Concurren... 展开 >>t Chemotherapy for Esophageal Cancer 收起 <<
Phase 3
Recruiting
December 31, 2022
China
... 展开 >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Recruiting
Beijing, China, 100021
Contact: Xin Wang, MD +861013311583220 beryl_wx2000@163.com 收起 <<
China, Beijing
... 展开 >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Recruiting
Beijing, Beijing, China, 100021
Contact: Zefen Xiao, MD 收起 <<
China, Beijing
... 展开 >> Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Recruiting
Beijing, Beijing, China, 100021
Contact: Zefen Xiao, MD 收起 <<
IMRT With or Without Concurren... 展开 >>t Chemotherapy for Esophageal Cancer 收起 <<
Phase 3
Recruiting
December 31, 2022
China
... 展开 >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Recruiting
Beijing, China, 100021
Contact: Xin Wang, MD +861013311583220 beryl_wx2000@163.com 收起 <<
China, Beijing
... 展开 >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Recruiting
Beijing, Beijing, China, 100021
Contact: Zefen Xiao, MD 收起 <<
China, Guangdong
... 展开 >>
Cancer Center Sun Yat-sen University
Recruiting
Guangzhou, Guangdong, China
Contact: Ming Shi, MD 86-2087343582 ext 86-2087343582 shiming@mail.sysu.edu.cn
Contact: Rong Ping Guo, MD 86-2087343117 ext 86-2087343117 guorongp@mail.sysu.edu.cn
Principal Investigator: Ming Shi, MD 收起 <<
China, Guangdong
... 展开 >>
Cancer Center Sun Yat-sen University
Recruiting
Guangzhou, Guangdong, China
Contact: Ming Shi 86-2087343582 ext 86-2087343582 shiming@mail.sysu.edu.cn
Contact: Ping Rong Guo 86-2087343117 ext 86-2087343117 guorongp@mail.sysu.edu.cn
Principal Investigator: Ming Shi 收起 <<
China, Guangdong
... 展开 >>
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,
Recruiting
Guangzhou, Guangdong, China, 500060
Contact: Ming Zhao, doctor +86 020 87343272 zhaoming@sysucc.org.cn
Contact: Tao Pan, doctor +86 020 87343271 pantao0909@hotmail.com 收起 <<
China, Guangdong
... 展开 >>
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,
Recruiting
Guangzhou, Guangdong, China, 500060
Contact: Ming Zhao, doctor +86 020 87343272 zhaoming@sysucc.org.cn 收起 <<
Extensive Stage Small Cell Lun... 展开 >>g Cancer 收起 <<
Phase 2
Unknown
December 2018
China, Liaoning
... 展开 >>
The First Affiliated Hospital of China Medical University
Recruiting
Shenyang, Liaoning, China, 110001
Contact: mingfang zhao, professor 13644055129 收起 <<
China, Guizhou
... 展开 >> The affiliated hospital of Guizhou medical university
Recruiting
Guiyang, Guizhou, China, 550004
Contact: Shengfa Su, PhD,MD 86-13608550432 sushengfa2005@163.com 收起 <<
China, Guizhou
... 展开 >> The affiliated hospital of Guizhou medical university
Recruiting
Guiyang, Guizhou, China, 550004
Contact: Shengfa Su, PhD,MD 86-13608550432 sushengfa2005@163.com 收起 <<
搜索
